📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial. (2023)

First Author: Warren RB

Attributed to: MICA: Psoriasis Stratification to Optimise Relevant Therapy (PSORT) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/bjd/ljad083

PubMed Identifier: 37120722

Publication URI: http://europepmc.org/abstract/MED/37120722

Type: Journal Article/Review

Volume: 189

Parent Publication: The British journal of dermatology

Issue: 2

ISSN: 0007-0963